1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT6R Antagonists : Mechanochemical Synthesis, In Vitro Pharmacological Properties and Glioprotective Activity
In addition to the canonical Gs adenylyl cyclase pathway, the serotonin type 6 receptor (5-HT6R) recruits additional signaling pathways that control cognitive function, brain development, and synaptic plasticity in an agonist-dependent and independent manner. Considering that aberrant constitutive and agonist-induced active states are involved in various pathological mechanisms, the development of biased ligands with different functional profiles at specific 5-HT6R-elicited signaling pathways may provide a novel therapeutic perspective in the field of neurodegenerative and psychiatric diseases. Based on the structure of SB-258585, an inverse agonist at 5-HT6R-operated Gs and Cdk5 signaling, we designed a series of 1-(arylsulfonyl-isoindol-2-yl)piperazine derivatives and synthesized them using a sustainable mechanochemical method. We identified the safe and metabolically stable biased ligand 3g, which behaves as a neutral antagonist at the 5-HT6R-operated Gs signaling and displays inverse agonist activity at the Cdk5 pathway. Inversion of the sulfonamide bond combined with its incorporation into the isoindoline scaffold switched the functional profile of 3g at Gs signaling with no impact at the Cdk5 pathway. Compound 3g reduced the cytotoxicity of 6-OHDA and produced a glioprotective effect against rotenone-induced toxicity in C8-D1A astrocyte cell cultures. In view of these findings, compound 3g can be considered a promising biased ligand to investigate the role of the 5-HT6R-elicited Gs and Cdk5 signaling pathways in neurodegenerative diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Biomolecules - 13(2022), 1 vom: 21. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Canale, Vittorio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.01.2023 Date Revised 31.01.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/biom13010012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35182118X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35182118X | ||
| 003 | DE-627 | ||
| 005 | 20231226052311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biom13010012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM35182118X | ||
| 035 | |a (NLM)36671397 | ||
| 035 | |a (PII)12 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Canale, Vittorio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT6R Antagonists |b Mechanochemical Synthesis, In Vitro Pharmacological Properties and Glioprotective Activity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2023 | ||
| 500 | |a Date Revised 31.01.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In addition to the canonical Gs adenylyl cyclase pathway, the serotonin type 6 receptor (5-HT6R) recruits additional signaling pathways that control cognitive function, brain development, and synaptic plasticity in an agonist-dependent and independent manner. Considering that aberrant constitutive and agonist-induced active states are involved in various pathological mechanisms, the development of biased ligands with different functional profiles at specific 5-HT6R-elicited signaling pathways may provide a novel therapeutic perspective in the field of neurodegenerative and psychiatric diseases. Based on the structure of SB-258585, an inverse agonist at 5-HT6R-operated Gs and Cdk5 signaling, we designed a series of 1-(arylsulfonyl-isoindol-2-yl)piperazine derivatives and synthesized them using a sustainable mechanochemical method. We identified the safe and metabolically stable biased ligand 3g, which behaves as a neutral antagonist at the 5-HT6R-operated Gs signaling and displays inverse agonist activity at the Cdk5 pathway. Inversion of the sulfonamide bond combined with its incorporation into the isoindoline scaffold switched the functional profile of 3g at Gs signaling with no impact at the Cdk5 pathway. Compound 3g reduced the cytotoxicity of 6-OHDA and produced a glioprotective effect against rotenone-induced toxicity in C8-D1A astrocyte cell cultures. In view of these findings, compound 3g can be considered a promising biased ligand to investigate the role of the 5-HT6R-elicited Gs and Cdk5 signaling pathways in neurodegenerative diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5-HT6 receptor inverse agonism/neutral antagonism | |
| 650 | 4 | |a Gs and Cdk5 signaling pathways | |
| 650 | 4 | |a glioprotective properties | |
| 650 | 4 | |a mechanochemical synthesis | |
| 650 | 4 | |a rotenone toxicity | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 700 | 1 | |a Trybała, Wojciech |e verfasserin |4 aut | |
| 700 | 1 | |a Chaumont-Dubel, Séverine |e verfasserin |4 aut | |
| 700 | 1 | |a Koczurkiewicz-Adamczyk, Paulina |e verfasserin |4 aut | |
| 700 | 1 | |a Satała, Grzegorz |e verfasserin |4 aut | |
| 700 | 1 | |a Bento, Ophélie |e verfasserin |4 aut | |
| 700 | 1 | |a Blicharz-Futera, Klaudia |e verfasserin |4 aut | |
| 700 | 1 | |a Bantreil, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Pękala, Elżbieta |e verfasserin |4 aut | |
| 700 | 1 | |a Bojarski, Andrzej J |e verfasserin |4 aut | |
| 700 | 1 | |a Lamaty, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Marin, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Zajdel, Paweł |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomolecules |d 2011 |g 13(2022), 1 vom: 21. Dez. |w (DE-627)NLM228347106 |x 2218-273X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:21 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biom13010012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |b 21 |c 12 | ||